Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 36 of 43

Adverse Effects: SGAs Versus SGAs (1 of 2)

The risk and severity of key adverse events was examined in a meta-analysis of individual second-generation antipsychotics (SGAs) compared with each other in head-to-head evaluations in pediatric use. The analysis found the following summary effects and statistically valid range of values for the effects, as defined by the 95-percent confidence interval (95% CI):

  • In comparing olanzapine with quetiapine, the risk for dyslipidemia is 3.5-fold greater with olanzapine (from 1.1-fold to 11.2-fold). The strength of evidence for this finding is low. There is no summary estimate for differences in weight during head-to-head comparisons of olanzapine and quetiapine.
  • In comparing olanzapine with risperidone, triglycerides are 17.3 mg/dL higher with olanzapine (from 3.5 to 31.1 mg/dL higher). The strength of evidence for this finding is moderate. Weight is 2.39 kg greater, on average, with olanzapine (from 1.5 kg to 3.3 kg greater). The strength of evidence for this finding is moderate.
  • In comparing olanzapine with aripiprazole, the risk of dyslipidemia is four times greater with olanzapine (from 1.25-fold to 12.5-fold). The strength of evidence for this finding is low. Weight is 4.1 kg greater, on average, with olanzapine (from 2.7 kg to 5.5 kg greater). The strength of evidence for this finding is low.
  •  In head-to-head comparisons of aripiprazole with quetiapine, triglycerides are 39.4 mg/dL lower with aripiprazole (from 7.4 to 71.3 mg/dL lower). The strength of evidence for this finding is low. Weight is 1.62 kg greater, on average, with quetiapine (from 0.3 to 3.0 kg greater). The strength of evidence for this finding is low.